<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04506723</url>
  </required_header>
  <id_info>
    <org_study_id>Stone-CL-01</org_study_id>
    <nct_id>NCT04506723</nct_id>
  </id_info>
  <brief_title>Comparison of Morphological and Radiological Data in Patients With Urolithiasis</brief_title>
  <official_title>Comparison of the Morphological Picture of the Renal Parenchyma With the Results of Mathematical Analysis of Intrarenal Transport of Contrast Medium in Computed Tomography in Patients With Urolithiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I.M. Sechenov First Moscow State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I.M. Sechenov First Moscow State Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study was to compare the ultrastructural changes in the renal parenchyma with&#xD;
      the results of postprocessing CT analysis with contrast enhancement in patients with&#xD;
      urolithiasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the features of interrenal transport of contrast agent and the structural state of the renal tissue</measure>
    <time_frame>1 month</time_frame>
    <description>The data of 3D analysis of CT of the kidneys in patients with urolithiasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the features of the morphological structure of glomeruli, tubules, perivascular and interstitial spaces of renal tissue in patients with urolithiasis</measure>
    <time_frame>2 weeks</time_frame>
    <description>The assessment will be based on intraoperative biopsy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Urolithiasis</condition>
  <arm_group>
    <arm_group_label>Patients with urolithiasis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with confirmed urolithiasis who is assigned to PCNL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without urolithiasis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with renal tumor without urolithiasis in history who is assigned to partial or radical nephrectomy due to renal tumor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous Nephrolithotomy</intervention_name>
    <description>PCNL will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed</description>
    <arm_group_label>Patients with urolithiasis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Partial nephrectomy</intervention_name>
    <description>Partial nephrectomy will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed</description>
    <arm_group_label>Patients without urolithiasis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical nephrectomy</intervention_name>
    <description>Nephrectomy will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed</description>
    <arm_group_label>Patients without urolithiasis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for experimental group:&#xD;
&#xD;
          1. Men and women &gt;18 years and &lt;45 years old;&#xD;
&#xD;
          2. Established diagnosis of urolithiasis that does not interfere with the processes of&#xD;
             urodynamics (there is no expansion of the overlying urinary tract);&#xD;
&#xD;
          3. Planned surgery - percutaneous nephrolithotripsy;&#xD;
&#xD;
          4. Stone size up to 20 mm., Patients with multiple small two-sided stones;&#xD;
&#xD;
          5. Patients with CT of the kidneys with contrast enhancement performed according to the&#xD;
             required protocol.&#xD;
&#xD;
        Exclusion Criteria for experimental group:&#xD;
&#xD;
          1. Age &lt; 18 years old or ASA&gt; 3;&#xD;
&#xD;
          2. With single kidney;&#xD;
&#xD;
          3. Patients with coral stones;&#xD;
&#xD;
          4. The presence of concomitant systemic pathology (DM, AH), as well as kidney disease&#xD;
             (glomerulonephritis), which can change the state of the renal parenchyma;&#xD;
&#xD;
          5. A history of injuries and surgical interventions on the kidneys, urinary tract, renal&#xD;
             vessels;&#xD;
&#xD;
          6. Taking nephrotropic drugs;&#xD;
&#xD;
          7. Systemic intake of nephrotoxic drugs;&#xD;
&#xD;
          8. Severe general somatic condition, making the operation impossible;&#xD;
&#xD;
          9. Pregnancy.&#xD;
&#xD;
        Inclusion Criteria for control group:&#xD;
&#xD;
          1. Men and women &gt;18 years and &lt;45 years old;&#xD;
&#xD;
          2. Absence of urolithiasis in the patient's anamnesis and in his family history;&#xD;
&#xD;
          3. Renal tumors which have undergone partial nephrectomy or nephrectomy;&#xD;
&#xD;
          4. Patients with CT renal data with contrast enhancement, performed according to the&#xD;
             required protocol.&#xD;
&#xD;
        Exclusion Criteria for control group:&#xD;
&#xD;
          1. Urolithiasis in anamnesis;&#xD;
&#xD;
          2. A history of trauma and surgical interventions on the kidneys, urinary tract, renal&#xD;
             vessels;&#xD;
&#xD;
          3. Intercurrent background;&#xD;
&#xD;
          4. Non-informative biopsy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dmitry Enikeev, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Sechenov University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dmitry Fiev, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sechenov University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dmitry Fiev, M.D., Ph.D.</last_name>
    <phone>+79265690949</phone>
    <email>fiev@mail.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute for Urology and Reproductive Health, Sechenov University.</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitry Enikeev, MD</last_name>
      <phone>+7 925 517 79 26</phone>
      <email>enikeev-dv@1msmu.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>I.M. Sechenov First Moscow State Medical University</investigator_affiliation>
    <investigator_full_name>Dmitry Enikeev, MD, PhD</investigator_full_name>
    <investigator_title>Deputy Director for Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Urinary Calculi</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

